Lantern Pharma enters $15.53M ATM equity offering agreement with ThinkEquity

Lantern Pharma Inc.

ATM Sales Agreement allows sale of up to $15,530,000 in common stock through ThinkEquity as agent.
Agent commission set at 3.0% of gross proceeds; sales at prevailing market prices on Nasdaq.
Company has no obligation to sell any shares; agreement terminates upon full sale or earlier termination.
Offering registered under existing S-3 shelf (File No. 333-279718); prospectus supplement filed July 3, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.